Abstract Details

Title Early Amantadine Treatment Does Not Delay Onset of Dyskinesias in Parkinson's Disease

Topic Movement Disorders

Presentation(s) P02 - (-)

Poster/Presentation
Number 080

Objective

Background BACKGROUND: Amantadine is the only medical therapy that has shown to reduce levodopa-induced dyskinesias (LID) in Parkinson's disease (PD) without worsening parkinsonian features (AAN level C evidence). The use of amantadine to try to delay onset of LID in PD has not been reported.

Design/Methods DESIGN/METHODS: Patients with a clinical diagnosis of PD seen at Movement Disorder Clinic Saskatchewan (MDCS) whose first visit was between January 1990 to December 2005 were identified. Inclusion criteria: no history of anti-PD drugs at first visit to MDCS; only subjects treated with levodopa for at least 5 years were included. Patients who received any anti-parkinsonian drug other than amantadine or levodopa were excluded.

Results RESULTS: 73 subjects met the inclusion and exclusion criteria. Group A (n=16) received amantadine prior to levodopa use while group B (n=57) did not. Groups were comparable in terms of gender and Hoehn & Yahr stage at visit 1. Mean onset age, disease duration at first levodopa and age at first levodopa use were similar. Dyskinesias were noted in 12/16 (75%) of group A and 36/57 (63%) of group B subjects. Dyskinesias at 5 years after starting levodopa were noted in 7/16 (44%) of group A and 20/57 (35%) of group B subjects. Time from first levodopa to dyskinesias was similar in both groups (5.2±2.8 vs 5.8±3.6 yrs). Each 10 year increase of onset age reduced the risk of LID by 27%. The risk of LID increased 18% for each 1 year increase in time from disease onset to first LD use.

Conclusions CONCLUSIONS: Amantadine treatment prior to use of levodopa did not delay onset of LID nor reduce the incidence of LID.

Authors/Disclosures
Alex Jahangirvand, MD PRESENTER	No disclosure on file
Ralph H. Benedict, PhD (University At Buffalo)	Dr. Benedict has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Roche. Dr. Benedict has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Sanofi. Dr. Benedict has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Bristol Meyers Squibb. Dr. Benedict has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Immunic Therapeutics. Dr. Benedict has received intellectual property interests from a discovery or technology relating to health care.
Alexander H. Rajput, MD, FAAN (Royal Univ Hosp/division of Neuro)	Dr. Rajput has received personal compensation in the range of $500-$4,999 for serving as a Peer reviewer with CQDM.

��ɫ��

��ɫ��